Evidence map›Paper›PMID 38232704›Full record

ArticleCell reports. Medicine2024

A four-cell pathway orchestrated by Flt3-L-dependent cDCs controls anti-tumor responses.

Konstantinos Aliazis, Vassiliki A Boussiotis

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Konstantinos AliazisDivision of Hematology-Oncology, Boston, MA 02115, USA; Department of Medicine, Boston, MA 02115, USA; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Vassiliki A BoussiotisDivision of Hematology-Oncology, Boston, MA 02115, USA; Department of Medicine, Boston, MA 02115, USA; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. Electronic address: vboussio@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · US

Funding

The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunityR01CA238263 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BOUSSIOTIS, VASSILIKI A · 2020 to 2024
$3.1M
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapyR01CA257672 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI VASSILIKI A BOUSSIOTIS, Ioannis Vlachos · 2023 to 2026
$2.8M
NCI NIH HHS R01 CA238263NCI NIH HHS R01 CA257672
6 · The paper itself

Abstract

A study by Régnier et al. shows that Flt3-ligand (FL) levels program two distinct mechanisms of anti-tumor immunity. Low FL levels allow recruitment of T effectors and T cell-mediated responses whereas high FL levels support recruitment of classical dendritic cells (cDC) and natural killer (NK) cells and NK-mediated anti-tumor responses.

Indexed as

Killer Cells, NaturalNeoplasmsHumansLymphocyte ActivationT-Lymphocytes

Identifiers

PMID38232704
PMCPMC10829860
OpenAlexW4390921276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.